Tags

Type your tag names separated by a space and hit enter

Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.

Abstract

BACKGROUND AND AIM

We assessed whether the two regimens of pegylated alpha-interferon-2b (PEG-IFN-alpha2b) plus ribavirin and pegylated alpha-interferon-2a (PEG-IFN-alpha2a) plus ribavirin showed differences in terms of sustained virological response, withdrawal due to side-effects and dose adjustment requirements in the treatment of naive chronic hepatitis C virus (HCV) patients.

METHODS

A prospective non-randomized, open-label comparison was made of naive HCV-infected patients undergoing standard 24- or 48-week treatment with two PEG-IFN combined with weight-based dosing regimen of ribavirin (PEG-IFN-alpha2a/ribavirin, n = 91; PEG-IFN-alpha2b/ribavirin, n = 92).

RESULTS

Sustained virological response was similar in PEG-IFN-alpha2a and PEG-IFN-alpha2b (65.9% vs 62%, P = 0.64), without differences according to genotype. In 117 patients with HCV genotype 1, the corresponding rates were 50.8% versus 46.6% (P = 0.713). Rapid virological response at 4 weeks, early virological response at 12 weeks and transient virological response were also similar. In the multivariate analysis, HCV genotype (odds ratio [OR] = 0.076, 95% confidence interval [CI] 0.029-0.198, P = 0.000) and presence of steatosis in the liver biopsy (OR = 2.799, 95% CI 1.362-5.755, P = 0.005) were significantly associated with response to antiviral therapy. The rate of withdrawals due to treatment-related adverse events was 13.2% in the group of PEG-IFN-alpha2a and 10.9% in the group of PEG-IFN-alpha2b. Dose modification of PEG-IFN was necessary in eight patients given PEG-IFN-alpha2a and in seven given PEG-IFN-alpha2b.

CONCLUSION

The two PEG-IFN plus ribavirin have comparable anti-HCV activity as shown by similar percentages of patients with sustained virological response.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Service of Hepatology, University Hospital Clinic, Department of Medicine, University of Valencia, Valencia, Spain. m.desamparados.escudero@uv.es

    , , , ,

    Source

    MeSH

    Adult
    Antiviral Agents
    Drug Therapy, Combination
    Female
    Hepacivirus
    Hepatitis C, Chronic
    Humans
    Interferon alpha-2
    Interferon-alpha
    Male
    Middle Aged
    Polyethylene Glycols
    Prospective Studies
    Recombinant Proteins
    Ribavirin
    Treatment Outcome
    Viral Load

    Pub Type(s)

    Comparative Study
    Controlled Clinical Trial
    Journal Article

    Language

    eng

    PubMed ID

    18422960

    Citation

    Escudero, Amparo, et al. "Pegylated Alpha-interferon-2a Plus Ribavirin Compared With Pegylated Alpha-interferon-2b Plus Ribavirin for Initial Treatment of Chronic Hepatitis C Virus: Prospective, Non-randomized Study." Journal of Gastroenterology and Hepatology, vol. 23, no. 6, 2008, pp. 861-6.
    Escudero A, Rodríguez F, Serra MA, et al. Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. J Gastroenterol Hepatol. 2008;23(6):861-6.
    Escudero, A., Rodríguez, F., Serra, M. A., Del Olmo, J. A., Montes, F., & Rodrigo, J. M. (2008). Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. Journal of Gastroenterology and Hepatology, 23(6), pp. 861-6. doi:10.1111/j.1440-1746.2008.05397.x.
    Escudero A, et al. Pegylated Alpha-interferon-2a Plus Ribavirin Compared With Pegylated Alpha-interferon-2b Plus Ribavirin for Initial Treatment of Chronic Hepatitis C Virus: Prospective, Non-randomized Study. J Gastroenterol Hepatol. 2008;23(6):861-6. PubMed PMID: 18422960.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study. AU - Escudero,Amparo, AU - Rodríguez,Felicidad, AU - Serra,Miguel A, AU - Del Olmo,Juan A, AU - Montes,Francisco, AU - Rodrigo,José M, Y1 - 2008/04/19/ PY - 2008/4/22/pubmed PY - 2008/11/18/medline PY - 2008/4/22/entrez SP - 861 EP - 6 JF - Journal of gastroenterology and hepatology JO - J. Gastroenterol. Hepatol. VL - 23 IS - 6 N2 - BACKGROUND AND AIM: We assessed whether the two regimens of pegylated alpha-interferon-2b (PEG-IFN-alpha2b) plus ribavirin and pegylated alpha-interferon-2a (PEG-IFN-alpha2a) plus ribavirin showed differences in terms of sustained virological response, withdrawal due to side-effects and dose adjustment requirements in the treatment of naive chronic hepatitis C virus (HCV) patients. METHODS: A prospective non-randomized, open-label comparison was made of naive HCV-infected patients undergoing standard 24- or 48-week treatment with two PEG-IFN combined with weight-based dosing regimen of ribavirin (PEG-IFN-alpha2a/ribavirin, n = 91; PEG-IFN-alpha2b/ribavirin, n = 92). RESULTS: Sustained virological response was similar in PEG-IFN-alpha2a and PEG-IFN-alpha2b (65.9% vs 62%, P = 0.64), without differences according to genotype. In 117 patients with HCV genotype 1, the corresponding rates were 50.8% versus 46.6% (P = 0.713). Rapid virological response at 4 weeks, early virological response at 12 weeks and transient virological response were also similar. In the multivariate analysis, HCV genotype (odds ratio [OR] = 0.076, 95% confidence interval [CI] 0.029-0.198, P = 0.000) and presence of steatosis in the liver biopsy (OR = 2.799, 95% CI 1.362-5.755, P = 0.005) were significantly associated with response to antiviral therapy. The rate of withdrawals due to treatment-related adverse events was 13.2% in the group of PEG-IFN-alpha2a and 10.9% in the group of PEG-IFN-alpha2b. Dose modification of PEG-IFN was necessary in eight patients given PEG-IFN-alpha2a and in seven given PEG-IFN-alpha2b. CONCLUSION: The two PEG-IFN plus ribavirin have comparable anti-HCV activity as shown by similar percentages of patients with sustained virological response. SN - 1440-1746 UR - https://www.unboundmedicine.com/medline/citation/18422960/Pegylated_alpha_interferon_2a_plus_ribavirin_compared_with_pegylated_alpha_interferon_2b_plus_ribavirin_for_initial_treatment_of_chronic_hepatitis_C_virus:_prospective_non_randomized_study_ L2 - https://doi.org/10.1111/j.1440-1746.2008.05397.x DB - PRIME DP - Unbound Medicine ER -